Trial Profile
Xeloda in Combination with Avastin as first-LIne treatment for HER2-negative metastatic Breast cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2007
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms XCALIBr
- Sponsors Roche
- 22 Jan 2007 New trial record.